Bringing together talented scientists, experienced leaders and innovative entrepreneurs.
Learn More
Developing and commercializing innovative drugs to treat cancer and orphan diseases and protect healthy tissues.
Learn More
Building a robust pipeline of oncology and orphan drugs focused in multiple indications.
Learn More
Developing powerful drugs to protect from radiation.
Learn More
Product Portfolio
Our pipeline currently includes nine product candidates being developed by us and our majority-owned subsidiaries, Incuron, LLC and Panacela Labs, Inc.
Lead Compounds
Our lead drug candidate, Entolimod (CBLB502), is being developed for dual indications as a radiation countermeasure through the FDA’s Animal Efficacy Rule and as a targeted cancer therapy and supportive care agent through the FDA’s traditional drug approval pathway.
Clinical Trials
We are aggressively pursuing development and commercialization of oncology drugs, orphan applications, and a radiation countermeasure.
Enrollment is open for our therapeutic clinical trials for various indications with oncology and orphan drug candidates in the pipeline.
Learn More About our Phase I oncology study with Entolimod (CBLB502)